## Medicaid Update



## New York State Medicaid Non-Invasive Prenatal Screening

Reminder: Non-Coverage Decision for Viscosupplementation

Reminder: Some Drug Categories are Excluded from

Coverage in Pharmacy and Medical Benefits (Cover)

of the Knee

Minivans

Reminder: Medicaid Requires Coordination of Benefits

for Trisomy 21, 18, and 13 Policy All Providers Medicaid Consumer Fact Sheets Now Available

Ambulette Providers (Category of Service 0602) Performing Medicaid Transports at the Taxi/Livery Level in Sedans and

Newborn Screening Amendment Requires Action from

Hospitals and Providers Treating Newborns and Infants

## Medicaid Enrollment Requirements and Compliance

**Deadlines for Managed Care Providers Provider Directory** 

Benefit Information Center" web page.

**Questions and Additional Information:** 

J7327

J7328

J7329

J7331

J7332

• FFS claim questions should be directed to the eMedNY Call Center at (800) 343-9000.

and Management (DPDM) by telephone at (518) 473-2160 or by email at FFSMedicaidPolicy@health.ny.gov.

**Questions and Additional Information:** 

email at PPNO@health.ny.gov.

Prenatal

Trisomy

Information document.

**Questions and Additional Information:** 

## 486-3209 or by email at PPNO@health.ny.gov. • MMC general coverage questions should be directed to the OHIP Division of Health Plan Contracting and Oversight (DHPCO) by email at covques@health.ny.gov or by telephone at (518) 473-1134.

Administration "Payment for Covered Outpatient Social Security <u>Drugs" website</u> and in the <u>eMedNY New York State Medicaid Fee-</u> for-Service Program Pharmacy Manual Policy Guidelines document.

Reminder: Some Drug Categories are Excluded from

**Coverage in Pharmacy and Medical Benefits** 

The New York State (NYS) Medicaid fee-for-service (FFS) and Medicaid

Managed Care (MMC) programs cover an extensive drug benefit providing access

to medically necessary drugs. There are, however, certain drug/drug classes that

are not covered by Medicaid for certain diagnoses due to federal and state rules,

outlined in both the Social Security Act §1927(d)(2), located on

article serves as a reminder of those exclusions for both the FFS and MMC program areas, which are as follows: • agents when used for the treatment of anorexia, weight loss or weight gain [additionally pursuant to New York Code, Rules and Regulations (NYCRR) Title 18 §505.3(g)(3)]; • agents when used for the treatment of sexual dysfunction unless such agents are used to treat a condition, other than sexual or erectile dysfunction, for which the agents have been approved by the Food and Drug Administration (FDA) [additionally pursuant to New York Social Services Law §365-a(4)(f)]; and when cosmetic agents growth used for or hair use (additionally §505.2(I)(5)). NYCRR 18 pursuant Title

- Medicaid FFS claim questions should be directed to the eMedNY Call Center at (800) 343-9000. • Medicaid FFS coverage and policy questions should be directed to the Office of Health Insurance Programs (OHIP) Division of Program
- Development and Management (DPDM) by telephone at (518) 473-2160 or by email FFSMedicaidPolicy@health.ny.gov. • Medicaid FFS Pharmacy coverage and policy questions should be directed to the Medicaid Pharmacy Policy Unit by telephone at (518)

• MMC Plan contact information can be found in the eMedNY New York State Medicaid Program Information for All Providers Managed Care

• MMC plan-specific policies and billing guidance for PADs can be found on the "New York State Medicaid Managed Care (MMC) Pharmacy

• MMC reimbursement, billing, and/or documentation requirement questions should be directed to the enrollees MMC Plan.

- olicy and Billing

**↑**Back to Top


**↑**Back to Top

Update.

the

Medicaid

**↑**Back to Top



evidence that the claims were initially billed to Medicare and/or third-party insurers and then were denied before seeking reimbursement from

Medicaid. The exception to this policy, in which providers may bill Medicaid directly without first receiving denials, is for items that are statutorily

not covered by the Medicare program. Providers are responsible for retaining the statutory exemptions from Medicare for audit or inspection.

Please note: When submitting an EOB, or other member related data, providers must ensure they are only submitting data relevant

the Medicaid member. All other patient information must be redacted prior to submission. It is important to ensure that you are not submitting Personally Identifiable Information (PII) or Protected Health Information (PHI) of non-Medicaid members to Medicaid.

and Management (DPDM) by telephone at (518) 473 2160 or by email at <a href="mailto:FFSMedicaidPolicy@health.ny.gov">FFSMedicaidPolicy@health.ny.gov</a>.

• Fee-for-service (FFS) claim questions should be directed to the eMedNY Call Center at (800) 343 9000.

• Specific medical pended claims questions should be directed to the Bureau of Medical Review Pended Claims Unit at (800) 342-3005 (Option 3). • Medicaid Managed Care (MMC) reimbursement, billing, and/or documentation requirement questions should be directed to enrollees MMC Plan. • MMC Plan contact information can be found in the <u>eMedNY New York State Medicaid Program Information for All Providers Managed Care</u> Information document.

• FFS coverage and policy questions should be directed to the Office of Health Insurance Programs (OHIP) Division of Program Development

**HCPCS Code Code Description** Hyaluronan or derivative, Durolane, for intra-articular injection, 1 mg J7318

\*Coverage will be available for compendia-supported uses. Please note: Medicaid will only cover administration fees for covered services. Coverage will continue for viscosupplementation for compendia-supported

Hyaluronan or derivative, Monovisc, for intra-articular injection, per dose

Hyaluronan or derivative, GelSyn-3, for intra-articular injection, 0.1 mg

Hyaluronan or derivative, Synojoynt, for intra-articular injection, 1 mg

Hyaluronan or derivative, TriLURON, for intra-articular injection, 1 mg

Hyaluronan or derivative, TriVisc, for intra-articular injection, 1 mg

• MMC general coverage questions should be directed to the OHIP, Division of Health Plan Contracting and Oversight (DHPCO) by email at covques@health.ny.gov or by telephone at (518) 473-1134. • MMC reimbursement, billing, and/or documentation requirement questions should be directed to the enrollees MMC Plan. • MMC Plan contact information can be found in the eMedNY New York State Medicaid Program Information for All Providers Managed Care Information document. New York State Medicaid Non-Invasive Prenatal Screening for Trisomy 21, 18, and 13 Policy Effective July 1, 2022, New York State (NYS) Medicaid fee-for-service (FFS) and Medicaid Managed Care (MMC) Plans [including mainstream MMC Plans, HIV (Human Immunodeficiency Virus) Special Needs Plans (SNPs), as well as Health and Recovery Plans (HARPs)], coverage of non-invasive prenatal trisomy screening, a form of non-invasive prenatal screening (NIPS), using cell-free fetal deoxyribonucleic acid (DNA), will be expanded to include members of any age, beyond the former coverage of individuals who meet risk criteria and/ or are 30 years of age or older. This coverage includes both singleton and twin pregnancies, but not higher multi-gestational pregnancies. Please note: This guidance is an update to the article titled NYS Medicaid Now Covers Non-invasive Prenatal Testing for Trisomy 21, 18, and 13, published in the October 2014 issue of the Medicaid Update, and to the article titled New York State Medicaid Expansion of Non-Invasive published Screening Policy, in August 2021 issue the

• FFS coverage and policy questions should be directed to the Office of Health Insurance Programs (OHIP) Division of Program Development

• FFS Pharmacy coverage and policy questions should be directed to the Medicaid Pharmacy Policy Unit by telephone at (518) 486-3209 or by

weigh benefits versus risks. Genetic counseling must also be provided to those who test positive for a fetal chromosomal abnormality. testing of a fetus by amniocentesis chorionic villus sampling will continue covered: or to o subsequent to a positive or high-risk score on a NIPS test; or o subsequent to an inconclusive test result in a high-risk pregnancy.

Information document. **↑**Back to Top

Virus - Pre-Exposure Prophylaxis), periodontal disease, sickle cell disease, smoking cessation, and tooth decay. Fact sheets are available in English, Spanish, Chinese, Russian, Haitian Creole, Bengali, Korean, Polish, Yiddish, Arabic and Italian. The most recently added fact sheet provides COVID-19 vaccination, testing, and treatment information and is currently only available in English. This fact sheet will be available in additional languages in the near future. **↑**Back to Top

Newborn Screening Amendment Requires Action from Hospitals and

**Providers Treating Newborns and Infants** 

Newborn screening is mandated in New York State (NYS) Public Health Law §2500-a and §2500-f. In 2022, the statute was amended to

add glucose-6-phosphate dehydrogenase (G6PD) deficiency to the list of newborn screening conditions in NYS. G6PD deficiency was not

newborns

by the

requires

panel of conditions screened

familial, racial, or ethnic risk of G6PD deficiency

law, effective June 20, 2022,

are admitted to the hospital for jaundice following discharge; or

added

instead.

have

regarding

Practitioner/

Prescriber

to

**How to Check Provider Enrollment Status** 

**Questions and Additional Information:** 

providerenrollment@health.ny.gov.

Please visit the eMedNY website.

**Provider Training:** 

PPNO@health.ny.gov.

Center" homepage.

"Provider Enrollment and Maintenance" web page.

how

enroll

is

on how to enroll is available on the eMedNY "Pharmacy Provider Enrollment" web page.

the

present with hemolytic anemia; or

present with hemolytic jaundice; or

Newborn Screening

present with early onset increasing neonatal jaundice persisting beyond the first week of life (bilirubin level greater than the 40th percentile for age in hours); or

Newborns and infants, who meet any one of the above criteria, must be tested for G6PD deficiency using a quantitative test.

**Program** through

be given a diagnostic test for G6PD

(African, Asian, Mediterranean, or

testing of

Middle

dried blood

deficiency

Eastern ancestry).

spots;

they:

**Hospital and Provider Requirements** Hospitals and providers caring for newborns and infants should put systems in place to ensure that infants meeting any of the above criteria be administered a quantitative test for G6PD deficiency. **Questions and Additional Information:** • Questions should be directed to (518) 473-7552 or <a href="mailto:nbsinfo@health.ny.gov">nbsinfo@health.ny.gov</a>. Screening Program".

published Prescribers article Non-Enrolled in the March 2021 Medicaid issue of **Pharmacy Enrollment** Effective September 1, 2022, MMC Plans will deny payment to pharmacies that are not enrolled as a fee-for-service (FFS) Medicaid Type provider. Pharmacies are furnishing providers that must enroll in the NYS Medicaid program to continue receiving payment. Information

the

on

Not Enrolled (MCO Credentialed as a non-billing Enroll with Medicaid as a billing provider\* MCO Provider) Enroll with Medicaid as a billing provider\* No result Not enrolled FFS **Enrolled (Qualified Billing Provider)** No action\*\* Not Enrolled (MCO Credentialed as a non-billing Enroll with Medicaid as a billing or an OPRA provider\*\* MCO Provider)

• FFS coverage and policy questions should be directed to the Medicaid Pharmacy Policy Unit by telephone at (518) 486-3209 or by email at

• MMC Plan contact information can be found on the NYS DOH "New York State Medicaid Managed Care (MMC) Pharmacy Benefit Information

Providers can check their enrollment status by utilizing the tools available on the NYS DOH "Medicaid Enrolled Provider Lookup" web

page. Search by entering your Medicaid Provider ID or your National Provider Identifier (NPI). Use the table below to determine your

current enrollment status and the corresponding action necessary as required from the "Medicaid Type" provided in the result.

Provider Directory-

Contact the New York Medicaid EHR Call Center at (877) 646-5410 for assistance. **Comments and Suggestions Regarding This Publication** Please contact the editor, Angela Lince, at <a href="mailto:medicaidupdate@health.ny.gov">medicaidupdate@health.ny.gov</a>. Like Us on Social Media:

> The Medicaid Update is a monthly publication of the New York State Department of Health Mary T. Bassett, M.D., M.P.H. **Kathy Hochul** Commissioner Governor

Brett R. Friedman

**Acting Medicaid Director** 

Office of Health Insurance Programs

Accordingly, ambulette providers may continue to use sedans and minivans to provide livery transports and such vehicles are not subject to DOT inspections. **Questions** Questions should be directed to the NYS DOH Medical Transportation Unit by telephone at (518) 473-2160 or by email at <a href="MedTrans@health.ny.gov">MedTrans@health.ny.gov</a>. **↑**Back to Top Medicaid Enrollment Requirements and Compliance Deadlines for Managed Care Providers As previously stated in the January 2018 issue of the Medicaid Update article titled Medicaid Managed Care and Children's Health Insurance Program Network Providers Must Enroll in the New York State Medicaid Program, §5005(b)(2) of the 21st Century Cures Act and 42 CFR §438.602 require all Medicaid Managed Care (MMC) network furnishing, ordering, prescribing, referring and attending (OPRA) providers to be enrolled with New York State (NYS) Medicaid program. Additionally, in accordance with 42 CFR §438.206(b)(4), MMC Plans will limit out-of-network services to services unable to be provided by network providers. **Out-of-Network and Non-Enrolled Providers** Effective September 1, 2022, MMC Plans will deny services from non-enrolled Medicaid or OPRA providers servicing more than ten members in the last 180 days. Out-of-network and non-enrolled MMC furnishing providers must enroll in Medicaid as a billing provider to continue receiving payment for services provided to an MMC member. NYS has adopted a process that will notify out-of-network providers to enroll in Medicaid. Out-of-network and non-enrolled Medicaid furnishing and OPRA providers servicing more than one MMC member are encouraged, without delay, to enroll now. Enrollment of Physicians, Nurse Practitioners, Physician Assistants, Podiatrists, Dentists, Optometrists, Audiologists, and Certified Nurse Midwives: • Providers and practitioners who wish to receive payment for covered NYS Medicaid services should apply as an "Individual Billing Medicaid". Information

<u>eMedNY</u>

• Providers who only wish to enroll as an OPRA provider (non-billing) may alternatively enroll as a OPRA provider on the eMedNY

Exceptions to the prescriber enrollment requirements for certain authorized prescribers are outlined in the Pharmacy Billing Guidance Exceptions

"Provider

**Enrollment** 

and

Maintenance"

page.

Update.

Pending

page.

**↑**Back to Top

**↑**Back to Top

Medicaid

enrollment check the status application in Providers applications may of their who have submitted weekly Network Provider Provider Listing file, updated on the <u>eMedNY "Medicaid</u> Managed Enrollment" Care Provider Type "Medicaid Type" **Enrollment Status Action Required Pharmacy** FFS **Enrolled (Qualified Billing Provider)** No action\*

Please enroll online for a provider seminar. For individual training requests, call (800) 343-9000. **Beneficiary Eligibility:** Call the Touchtone Telephone Verification System at (800) 997-1111. **Medicaid Prescriber Education Program:** 

**New York State** 

Department of Health

State of New York

• DOH Prescriber Education Program page • Prescriber Education Program in partnership with SUNY **eMedNY** For a number of services, including: change of address, updating an enrollment file due to an ownership change, enrolling another NPI, or revalidating an existing enrollment, please visit eMedNY's Provider Enrollment page and choose the appropriate link based on provider type. NY Medicaid Electronic Health Record (EHR) Incentive Program

communication, interpretation of results with patients and health care providers discuss the benefits and risks of all prenatal genetic testing, including NIPS tests, with a genetic counselor or other health care provider before considering such testing or making any decisions about their pregnancy." Providers can refer to the FDA "Genetic Non-Invasive Prenatal Screening Tests May Have False Results: FDA Safety Communication" web page for a full-list of recommendations for patients and providers. **Reminders:** • Genetic counseling is covered by Medicaid and should be provided to pregnant members prior to non-invasive prenatal testing to Prenatal Diagnostic testing (e.g., cytogenetic analysis or molecular genetic testing) for suspected aneuploidies continues to be covered if medically necessary. · Cell-free fetal DNA testing should not be offered to members who are pregnant with three or more fetuses because it has not been sufficiently evaluated in these groups. • Micro-deletion testing, in conjunction with non-invasive trisomy testing, is not reimbursable. **Questions and Additional Information:** • Consistent with existing policy, NYS Regulations at 18 New York Codes, Rules and Regulations (NYCRR) §505.7(g)(4) requires providers to order tests, individually. No payment will be made for tests ordered as groupings or combinations of tests. For more information and for additional regulations pertaining to laboratory services, providers should visit the NYCRR "Title: Section 505.7 - Laboratory Services" web page. • FFS billing and claim questions should be directed to the eMedNY Call Center at (800) 343 9000. • FFS coverage and policy questions should be directed to the Office of Health Insurance Programs (OHIP), Division of Program Development and Management (DPDM), by telephone at (518) 473 2160 or by email at FFSMedicaidPolicy@health.ny.gov. • MMC reimbursement, billing, and/or documentation requirement questions should be directed to enrollee MMC Plans. • MMC Plan contact information can be found in the eMedNY New York State Medicaid Program Information for All Providers Managed Care

Reminder: Non-Coverage Decision for Viscosupplementation of the Knee Effective May 19, 2022, for New York State (NYS) Medicaid fee-for-service (FFS), and effective June 23, 2022, for Medicaid Managed Care (MMC), the Medicaid program will be implementing system enhancements to reinforce the coverage decision described in the following sources: • Medicaid Redesign Team (MRT) coverage update, titled Synvisc and SynviscOne®, located on the NYS Department of Health (DOH) "Synvisc and SynviscOne®" web page, and Viscosupplementation of the Knee: Non-Coverage Decision article published in the March 2014 issue of the Medicaid Update, relating to non-coverage for viscosupplementation of the knee for an MMC enrollee with a diagnosis of osteoarthritis of the knee. There will be no reimbursement provided by Medicaid when the Healthcare Common Procedure Code System (HCPCS) codes, provided in the table below, are used for the treatment of osteoarthritis of the knee: J7320 Hyaluronan or derivative, GenVisc 850, for intra-articular injection, 1 mg J7321 Hyaluronan or derivative, Hyalgan, Supartz, or Visco-3 for intra-articular injection, per dose\* J7322 Hyaluronan or derivative, Hymovis, for intra-articular injection, 1 mg J7323 Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose\* J7324 Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose J7325 Hyaluronan or derivative, Synvisc or Synvisc-One, for intra-articular injection, J7326 Hyaluronan or derivative, Gel-One, for intra-articular injection, per dose\*

uses. For additional guidance regarding viscosupplementation claim requirements, the viscosupplementation Clinical Criteria Worksheet can be found on the NYS Department of Health (DOH) "New York State Medicaid Fee-for-Service Practitioner Administered Drug Policies and Billing Guidance" web page.

**Considerations** On April 19, 2022, the U.S. Food and Drug Administration (FDA) issued a warning of the risk of false results, inappropriate use, and inappropriate non-invasive prenatal screening tests. Per their "[t]he FDA recommends that

All Providers **Medicaid Consumer Fact Sheets Now Available** Medicaid consumer fact sheets, focused on prevention, treatment, and management of health conditions, as well as relevant Medicaid benefits that can be used to help members stay healthy, are available on the New York State (NYS) Department of Health (DOH) "MRT II Policies and Guidance" web page. Topics include asthma control, chronic kidney disease, Coronavirus Disease 2019 (COVID-19), diabetes, high blood pressure, HIV-PrEP (Human Immunodeficiency

• For additional information, providers and families may visit the NYS Department of Health (DOH) Wadsworth Center web page, titled "Newborn" **↑**Back to Top **Ambulette Providers (Category of Service 0602) Performing Medicaid** Transports at the Taxi/Livery Level in Sedans and Minivans The purpose of this update is to align existing New York State (NYS) Medicaid Transportation policy with NYS Department of Transportation (DOT) policy. The NYS Department of Health (DOH) recognizes that some ambulette providers added sedans and minivans to their fleets to transport ambulatory patients in need of curb-to-curb transportation billable to Medicaid under livery procedure codes. NYS DOH has become aware that DOT will no longer inspect these sedans and minivans. Consistent with current practices of the DOT, only Medicaid transports performed by ambulette providers in ambulette vehicles, must be performed in vehicles inspected semi-annually by the DOT and by drivers certified under Article 19A of Vehicle and Traffic Law.

**Criteria for NYS Medicaid Enrollment** Not all practitioner and pharmacy providers will meet criteria to qualify for enrollment. Providers can review the provider manuals available on the eMedNY "Provider Manuals" web page and on the eMedNY "Provider Enrollment and Maintenance" web page by selecting the appropriate provider type from the right-hand box titled "Provider List Filter".

available

OPRA Enrolled (Qualified non-billing Provider) No action Enroll with Medicaid as billing provider\*\* or if eligible as a OPRA No result Not Enrolled provider \*Pharmacy providers not enrolled in Medicare must also enroll in Medicare as a participating provider. \*\*Some billing practitioners do not require Medicare enrollment, see enrollment index for your profession for more information.

• Enrollment questions may be directed to the Medicaid Enrollment Unit by telephone at (800) 343-9000 or by email

• MMC network related questions should be directed to the enrollee's MMC Plan.

**Office of the Medicaid Inspector General:** For suspected fraud, waste or abuse complaints/allegations, call 1-877-87FRAUD, (877) 873-7283, or visit Office of Medicaid Inspector General (OMIG) web site.

**Provider Manuals/Companion Guides, Enrollment Information/Forms/Training Schedules:** 

Please call (866) 307-5549 (available Thursday PM for one week for the current week's amount).

Providers wishing to listen to the current week's check/EFT amounts:

For questions about billing and performing MEVS transactions:

Please call the eMedNY Call Center at (800) 343-9000.

For current information on best practices in pharmacotherapy, please visit the following websites: